vs

Side-by-side financial comparison of Editas Medicine, Inc. (EDIT) and USCB FINANCIAL HOLDINGS, INC. (USCB). Click either name above to swap in a different company.

Editas Medicine, Inc. is the larger business by last-quarter revenue ($24.7M vs $22.2M, roughly 1.1× USCB FINANCIAL HOLDINGS, INC.). USCB FINANCIAL HOLDINGS, INC. runs the higher net margin — 6.1% vs -22.7%, a 28.9% gap on every dollar of revenue. On growth, USCB FINANCIAL HOLDINGS, INC. posted the faster year-over-year revenue change (14.7% vs -19.2%). USCB FINANCIAL HOLDINGS, INC. produced more free cash flow last quarter ($42.5M vs $-36.4M). Over the past eight quarters, Editas Medicine, Inc.'s revenue compounded faster (366.9% CAGR vs 12.3%).

Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

USCB Financial Holdings, Inc. is a U.S.-headquartered bank holding company that offers comprehensive retail and commercial banking services, including deposit products, personal and business loans, wealth management, and digital banking tools. It primarily serves individual consumers, small and medium-sized enterprises, and local corporate clients across its operating regions in the United States, prioritizing personalized customer experiences and community-oriented financial services.

EDIT vs USCB — Head-to-Head

Bigger by revenue
EDIT
EDIT
1.1× larger
EDIT
$24.7M
$22.2M
USCB
Growing faster (revenue YoY)
USCB
USCB
+33.9% gap
USCB
14.7%
-19.2%
EDIT
Higher net margin
USCB
USCB
28.9% more per $
USCB
6.1%
-22.7%
EDIT
More free cash flow
USCB
USCB
$78.9M more FCF
USCB
$42.5M
$-36.4M
EDIT
Faster 2-yr revenue CAGR
EDIT
EDIT
Annualised
EDIT
366.9%
12.3%
USCB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EDIT
EDIT
USCB
USCB
Revenue
$24.7M
$22.2M
Net Profit
$-5.6M
$1.4M
Gross Margin
Operating Margin
-31.3%
14.7%
Net Margin
-22.7%
6.1%
Revenue YoY
-19.2%
14.7%
Net Profit YoY
87.6%
-80.3%
EPS (diluted)
$0.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EDIT
EDIT
USCB
USCB
Q4 25
$24.7M
$22.2M
Q3 25
$7.5M
$25.0M
Q2 25
$3.6M
$24.4M
Q1 25
$4.7M
$22.8M
Q4 24
$30.6M
$23.0M
Q3 24
$61.0K
$21.5M
Q2 24
$513.0K
$20.5M
Q1 24
$1.1M
$17.6M
Net Profit
EDIT
EDIT
USCB
USCB
Q4 25
$-5.6M
$1.4M
Q3 25
$-25.1M
$8.9M
Q2 25
$-53.2M
$8.1M
Q1 25
$-76.1M
$7.7M
Q4 24
$-45.4M
$6.9M
Q3 24
$-62.1M
$6.9M
Q2 24
$-67.6M
$6.2M
Q1 24
$-62.0M
$4.6M
Operating Margin
EDIT
EDIT
USCB
USCB
Q4 25
-31.3%
14.7%
Q3 25
-325.4%
47.3%
Q2 25
-1440.6%
44.0%
Q1 25
-1635.1%
44.2%
Q4 24
-152.2%
39.6%
Q3 24
-107649.2%
42.5%
Q2 24
-14016.2%
39.8%
Q1 24
-5902.3%
34.3%
Net Margin
EDIT
EDIT
USCB
USCB
Q4 25
-22.7%
6.1%
Q3 25
-333.0%
35.8%
Q2 25
-1487.8%
33.4%
Q1 25
-1633.5%
33.5%
Q4 24
-148.3%
30.0%
Q3 24
-101870.5%
32.3%
Q2 24
-13178.8%
30.3%
Q1 24
-5458.1%
26.2%
EPS (diluted)
EDIT
EDIT
USCB
USCB
Q4 25
$0.03
Q3 25
$-0.28
$0.45
Q2 25
$-0.63
Q1 25
$-0.92
Q4 24
$-0.55
Q3 24
$-0.75
$0.35
Q2 24
$-0.82
Q1 24
$-0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EDIT
EDIT
USCB
USCB
Cash + ST InvestmentsLiquidity on hand
$146.6M
$38.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$27.3M
$217.2M
Total Assets
$186.5M
$2.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EDIT
EDIT
USCB
USCB
Q4 25
$146.6M
$38.5M
Q3 25
$165.6M
$56.8M
Q2 25
$178.5M
$54.8M
Q1 25
$221.0M
$98.0M
Q4 24
$269.9M
$77.0M
Q3 24
$265.1M
$38.5M
Q2 24
$279.1M
$77.3M
Q1 24
$296.2M
$126.5M
Total Debt
EDIT
EDIT
USCB
USCB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$57.4M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
EDIT
EDIT
USCB
USCB
Q4 25
$27.3M
$217.2M
Q3 25
$13.5M
$209.1M
Q2 25
$19.2M
$231.6M
Q1 25
$62.4M
$225.1M
Q4 24
$134.3M
$215.4M
Q3 24
$175.6M
$213.9M
Q2 24
$232.0M
$201.0M
Q1 24
$294.4M
$195.0M
Total Assets
EDIT
EDIT
USCB
USCB
Q4 25
$186.5M
$2.8B
Q3 25
$201.8M
$2.8B
Q2 25
$210.6M
$2.7B
Q1 25
$263.7M
$2.7B
Q4 24
$341.6M
$2.6B
Q3 24
$327.6M
$2.5B
Q2 24
$384.8M
$2.5B
Q1 24
$440.3M
$2.5B
Debt / Equity
EDIT
EDIT
USCB
USCB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.43×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EDIT
EDIT
USCB
USCB
Operating Cash FlowLast quarter
$-36.4M
$42.8M
Free Cash FlowOCF − Capex
$-36.4M
$42.5M
FCF MarginFCF / Revenue
-147.3%
191.4%
Capex IntensityCapex / Revenue
0.2%
1.4%
Cash ConversionOCF / Net Profit
31.40×
TTM Free Cash FlowTrailing 4 quarters
$95.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EDIT
EDIT
USCB
USCB
Q4 25
$-36.4M
$42.8M
Q3 25
$-30.8M
$20.1M
Q2 25
$-50.2M
$18.0M
Q1 25
$-47.8M
$14.6M
Q4 24
$-50.8M
$34.8M
Q3 24
$-52.6M
$11.3M
Q2 24
$-57.1M
$18.3M
Q1 24
$-49.9M
$8.1M
Free Cash Flow
EDIT
EDIT
USCB
USCB
Q4 25
$-36.4M
$42.5M
Q3 25
$-31.3M
$20.0M
Q2 25
$18.0M
Q1 25
$-47.9M
$14.6M
Q4 24
$-51.3M
$34.5M
Q3 24
$-55.5M
$11.2M
Q2 24
$-60.6M
$18.2M
Q1 24
$-51.7M
$8.0M
FCF Margin
EDIT
EDIT
USCB
USCB
Q4 25
-147.3%
191.4%
Q3 25
-414.6%
80.3%
Q2 25
73.7%
Q1 25
-1028.6%
63.9%
Q4 24
-167.6%
150.2%
Q3 24
-90998.4%
52.2%
Q2 24
-11804.3%
88.8%
Q1 24
-4558.9%
45.4%
Capex Intensity
EDIT
EDIT
USCB
USCB
Q4 25
0.2%
1.4%
Q3 25
5.7%
0.5%
Q2 25
0.0%
0.2%
Q1 25
2.4%
0.2%
Q4 24
1.8%
1.4%
Q3 24
4788.5%
0.4%
Q2 24
681.1%
0.4%
Q1 24
164.8%
0.5%
Cash Conversion
EDIT
EDIT
USCB
USCB
Q4 25
31.40×
Q3 25
2.25×
Q2 25
2.22×
Q1 25
1.91×
Q4 24
5.05×
Q3 24
1.63×
Q2 24
2.95×
Q1 24
1.75×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons